New pain block could cut opioid use after mastectomy
NCT ID NCT07562945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a continuous nerve block using the numbing drug ropivacaine can reduce pain, inflammation, and opioid use in women undergoing mastectomy for breast cancer. Forty women will be randomly assigned to receive the nerve block or standard pain care. Researchers will measure pain scores, opioid consumption, and markers of inflammation in the first 24 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ropivacaine
- What this could lead to
- If it works, this could offer a better way to manage pain after mastectomy, reducing the need for opioids and possibly improving recovery.
- What could go wrong
- This is a small, early-stage trial with only 40 participants, so results may not apply to everyone. The nerve block carries rare risks like infection or allergic reaction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ngoerah Hospital
Denpasar, Bali, 80113, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?